Trials / Active Not Recruiting
Active Not RecruitingNCT07073690
Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China
Real-World Treatment Patterns and Outcomes of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes (LR-MDS) in China ('REACH' Study)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the treatment patterns and clinical outcomes in adults with lower-risk MDS (LR-MDS) who were erythropoiesis-stimulating agents (ESA)-naïve and received luspatercept treatment in China
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Luspatercept | According to the product label |
Timeline
- Start date
- 2025-04-18
- Primary completion
- 2025-11-26
- Completion
- 2025-11-26
- First posted
- 2025-07-18
- Last updated
- 2025-07-18
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07073690. Inclusion in this directory is not an endorsement.